# Mepolizumab

## Nucala 100mg inj

##### 臨採

| TAH Drug Code      | [INUC](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=INUC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Severe refractory eosinophilic asthma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Asthma: Adults and Age >12 years old: 100 mg administered by subcutaneous (SC) injection once every 4 weeks. Age 6-11 years old: 40 mg administered by subcutaneous (SC) injection once every 4 weeks. Eosinophilic granulomatosis with polyangiitis: Adults and Age >12 years old: 300 mg administered by subcutaneous (SC) injection once every 4 weeks.                                                                                                                                                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Hypersensitivity to mepolizumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | >10%: Central nervous system: Headache (19%) Local: Injection site reaction (8% to 15%) 1% to 10%: Central nervous system: Fatigue (5%) Dermatologic: Eczema (3%), pruritus (3%) Gastrointestinal: Upper abdominal pain (3%) Genitourinary: Urinary tract infection (3%) Hypersensitivity: Hypersensitivity reaction (eosinophilic granulomatosis: 4%), angioedema (eosinophilic granulamatosis: 1%) Immunologic: Immunogenicity (asthma: 6%, eosinophilic granulomatosis: <2%; neutralizing: <1%) Infection: Influenza (3%) Neuromuscular & skeletal: Back pain (5%), muscle spasm (3%) Frequency not defined: Hypersensitivity: Delayed hypersensitivity Infection: Herpes zoster |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/mepolizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

